Nasus Pharma

Yahoo Finance • 2 months ago

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can achieve faster and higher absorption of e... Full story

Yahoo Finance • 3 months ago

Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program

TEL AVIV, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical... Full story